25.06 07:48 | dpa-AFX: Roche's Ocrevus Subcutaneous Injection For Multiple Sclerosis Gets Approval In EU |
25.06 07:24 | Roche erhält EU-Zulassung für Multiple-Sklerose-Mittel |
25.06 07:11 | dpa-AFX: *ROCHE RECEIVES EU APPROVAL FOR OCREVUS SUBCUTANEOUS FOR MULTIPLE SCLEROSIS TREATMENT |
25.06 07:00 | Press Release: Roche's OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis |
25.06 07:00 | Press Release: Roche's OCREVUS subcutaneous -2- |
24.06 17:42 | Aktien Schweiz fest - Pharmawerte gesucht |
24.06 09:11 | dpa-AFX: Barclays belässt Roche auf 'Equal Weight' - Ziel 230 Franken |
24.06 07:00 | Press Release: Roche launches new analytical units for cobas(R) pro integrated solutions delivering greater efficiency and capacity to laboratories |
21.06 17:40 | Aktien Schweiz schließen schwächer |
21.06 03:45 | dpa-AFX: Sarepta Therapeutics' Elevidys Approved By FDA For Duchenne Muscular Dystrophy; Stock Surges |
20.06 18:59 | dpa-AFX: ANALYSE-FLASH: UBS belässt Roche auf 'Neutral' - Ziel 238 Franken |
20.06 18:59 | dpa-AFX: UBS belässt Roche auf 'Neutral' - Ziel 238 Franken |
20.06 17:53 | Aktien Schweiz freundlich - Zykliker und Finanzwerte gesucht |
20.06 07:25 | dpa-AFX: Roche Unveils Advanced Test For Enhanced B-Cell Lymphoma Diagnosis |
20.06 07:10 | dpa-AFX: *ROCHE LAUNCHES VENTANA KAPPA AND LAMBDA DUAL ISH MRNA PROBE COCKTAIL ASSAY |
20.06 07:00 | Press Release: Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma |
19.06 17:48 | Aktien Schweiz schließen nach impulsarmem Handel gut behauptet |
18.06 17:44 | Aktien Schweiz etwas fester - Nestle und Novartis bremsen SMI |
18.06 15:55 | dpa-AFX: Roche, Ascidian Announce Partnership For RNA Exon Editing Therapeutics In Neurological Diseases |
18.06 15:13 | Roche und Ascidian Therapeutics kooperieren bei RNA-Gene-Editierung |
|